Study of a new drug for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed. The goal is to see if it helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic non-small cell lung cancer (NSCLC) confirmed by biopsy or other tests.
- You are able to do most daily activities with little or no help (ECOG score 0 or 1).
- Your doctor expects you to live at least 3 more months.
- Any side effects from prior cancer treatments (except hair loss and fatigue) have mostly resolved.
- Your major organs and bone marrow are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SSGJ-707 for people with advanced non-small cell lung cancer who have not had prior treatment. It aims to see if the drug can help shrink tumors and improve outcomes.
This trial tests a new drug called SSGJ-705, given alone or with other treatments, for advanced cancers that have a specific protein (HER2) on their surface. It is for people with lung, breast, or stomach cancer that has spread and hasn't gotten better with other treatments.
This trial tests a new drug called SSGJ-707 for people with colorectal cancer that has spread. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new drug called JS212 combined with other treatments for people with advanced or spreading lung cancer. It aims to see if the combination can help shrink tumors or slow the disease.
This phase 1 trial tests a new targeted drug (SSGJ-705) for people with advanced solid tumors or lymphomas. Doctors will check safety and find the best dose, and there may be a chance the drug helps shrink or control the cancer.
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
Hear when a new First-line Advanced NSCLC Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.